{"nctId":"NCT02164578","briefTitle":"Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk","startDateStruct":{"date":"2015-04","type":"ACTUAL"},"conditions":["Type 2 Diabetic Patients"],"count":179,"armGroups":[{"label":"Rivaroxaban","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban"]},{"label":"Aspirin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aspirin"]}],"interventions":[{"name":"Rivaroxaban","otherNames":[]},{"name":"Aspirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes duration between 2 and 20 years\n* Two or more components of metabolic syndrome:\n\n  * HDL-cholesterol \\< 1.0 mmol/L (in males) or \\< 1.3 mmol/L (in females)\n  * Elevated triglycerides (\\> 1.7 mmol/L)\n  * Elevated blood pressure (\\> 130 mmHg systolic and/or \\>85 mmHg diastolic or antihypertensive treatment)\n  * Elevated waist circumference (\\> 102 cm in males, \\> 85 cm in females)\n* Or at least one of the following\n\n  * Carotid ultrasound showing an IMT \\> 1 mm and plaque of carotid artery or\n  * Left ventricular hypertrophy or\n  * Increased UACR in the absence of other renal diseases than diabetic nephropathy\n* Increased hsCRP (\\> 2 mg/l but \\< 10 mg/l) at or within 6 months prior to screening and/or increased PAI 1 (\\> 15 ng/ml) at or within 6 months prior to screening (the historical hsCRP or PAI 1 value can be used only if the patient was in stable conditions regarding the concomitant diseases and statin therapy since the time point of measurement)\n* Stable treatment with statins (if tolerated/clinically indicated)\n* Age 40 - 75 years\n\nExclusion Criteria:\n\n* Major cardiovascular (CV) event with need for oral anticoagulation or platelet inhibitor therapy or acute coronary syndrome \\< 12 month before study entry\n* Sustained uncontrolled hypertension: systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 100 mmHg\n* Hypersensitivity to the active substance or to any of the excipients\n* Active clinically significant bleeding\n* Lesion or condition, if considered to be a significant risk for major bleeding\n* Concomitant treatment of acute coronary syndrome (ACS) with antiplatelet therapy in patients with a prior stroke or a transient ischemic attack (TIA)\n* Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C\n* Chronic renal failure with eGFR \\< 15 ml/min (MDRD formula)\n* Pregnant or breast-feeding woman and woman without adequate method of contraception.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Post-ischemic Forearm Blood Flow","description":"Change of maximal postischemic forearm blood flow during reactive hyperaemia after 5 min of forearm ischemia (FBF max. ml/100ml).\n\nDifference of change in post-ischemic forearm blood flow measured by venous occlusion plethysmography at baseline and after 20 weeks treatment with rivaroxaban or aspirin.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"4.69"},{"groupId":"OG001","value":"1.00","spread":"5.27"}]}]}]},{"type":"PRIMARY","title":"Change in Pulse Wave Velocity","description":"Change in pulse wave velocity as a marker of arterial stiffness (measured by IEM Mobil-O-Graph)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.62"},{"groupId":"OG001","value":"0.51","spread":"0.57"}]}]}]},{"type":"SECONDARY","title":"Change in Post-ischemic Forearm Blood Flow","description":"Difference of change in post-ischemic forearm blood flow measured by venous occlusion plethysmography at baseline and after 52 weeks treatment with rivaroxaban or aspirin.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.11","spread":"8.83"},{"groupId":"OG001","value":"1.56","spread":"5.34"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Wave Velocity","description":"Change in pulse wave velocity as a marker for arterial stiffness (measured by IEM Mobil-O-Graph)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.44"},{"groupId":"OG001","value":"0.14","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Change in Skin Blood Flow","description":"Change in skin blood flow for assessment of peripheral skin microcirculatory function (measured by laserdopplerfluxmetry; LDF)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.47","spread":"44.7"},{"groupId":"OG001","value":"-6.01","spread":"34.0"}]}]}]},{"type":"SECONDARY","title":"Change in Skin Blood Flow","description":"Change in skin blood flow for assessment of peripheral skin microcirculatory function (measured by laserdopplerfluxmetry; LDF)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","spread":"45.1"},{"groupId":"OG001","value":"5.8","spread":"59.5"}]}]}]},{"type":"SECONDARY","title":"Major Bleeding","description":"Major bleeding defined as clinically overt and associated with one of the following: 1) reduction of hemoglobin level of 2 g/L or 2) required transfusion of at least 2 units of red cells or, involved a critical organ or was fatal, in accordance with the recommendation of the International Society on Thrombosis and Hemostasis (ISTH).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Major Bleeding","description":"Major bleeding defined as clinically overt and associated with one of the following: 1) reduction of hemoglobin level of 2 g/L or 2) required transfusion of at least 2 units of red cells or, involved a critical organ or was fatal, in accordance with the recommendation of the International Society on Thrombosis and Hemostasis (ISTH).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinically Relevant Non-major (CRNM) Bleeding","description":"Clinically relevant non-major (CRNM) bleeding defined as at least one of the following:\n\n* spontaneous skin hematoma of at least 25 cm\n* spontaneous nose bleeding of more than 5 minutes duration\n* macroscopic hematuria, either spontaneous or, if associated with an intervention, lasting more than 24 hours\n* spontaneous rectal bleeding (more than spotting on toilet paper)\n* gingival bleeding for more than 5 minutes\n* bleeding leading to hospitalization and/or requiring surgical treatment\n* bleeding leading to a transfusion of less than 2 units of whole blood or red cells\n* any other bleeding event considered clinically relevant by the investigator","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinically Relevant Non-major (CRNM) Bleeding","description":"Clinically relevant non-major (CRNM) bleeding defined as at least one of the following:\n\n* spontaneous skin hematoma of at least 25 cm\n* spontaneous nose bleeding of more than 5 minutes duration\n* macroscopic hematuria, either spontaneous or, if associated with an intervention, lasting more than 24 hours\n* spontaneous rectal bleeding (more than spotting on toilet paper)\n* gingival bleeding for more than 5 minutes\n* bleeding leading to hospitalization and/or requiring surgical treatment\n* bleeding leading to a transfusion of less than 2 units of whole blood or red cells\n* any other bleeding event considered clinically relevant by the investigator","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":89},"commonTop":[]}}}